Cardiology · Heart FailureTrial Updateclinicalmid-term

Dapagliflozin Evaluated for Right Ventricular-Pulmonary Artery Coupling Post-OPCAB

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/21/2026, 12:31:03 AM

Assessment confidence: 64% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The ongoing trial of dapagliflozin in heart failure patients post-surgery could significantly impact its clinical application and market positioning. Positive outcomes may lead to expanded indications, enhancing competitive strategies against other heart failure therapies. Regulatory context from FDA (Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026) supports the near-term read. Assessment grounded in 14 ranked evidence items (7 high-relevance).

Strategic Assessment

Positive results may enhance dapagliflozin's positioning in heart failure treatment, influencing competitive strategies for similar agents. The strongest clinical anchor is Effectiveness of Video Monitoring and Care Transition for Heart Failure Patients (EVIT-HF): Randomized Clinical Trial (ClinicalTrials.gov), sub-indication match (cardiology); entity match (heart failure patients). In cardiology, 8 regulatory and 1 competitive items passed relevance filtering for Dapagliflozin.

Competitive Pressure

The most relevant competitive pressure comes from Digital Management Improves Outcomes in Early Cardiogenic Shock Patients (Humanexa Signals) — sub-indication match (cardiology). This trial could provide insights into the cardiovascular benefits of dapagliflozin, potentially expanding its use beyond diabetes management.

Regulatory Outlook

Regulatory risk is concentrated around Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026 (FDA). Sub-indication match (cardiology). Successful trial results could pave the way for regulatory submissions to expand dapagliflozin's label, impacting compliance and approval timelines for new indications.

Key Risks

Elevated medium regulatory exposure for Dapagliflozin could delay market entry or constrain labeling if agency review intensifies.
Regulatory risk from FDA (Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026) could weigh on Dapagliflozin through agency review timelines and labeling constraints if follow-through weakens.
Clinical risk from ClinicalTrials.gov (ImpleMEntation of Digital-first Care deLiverY Model for Heart Failure in Uganda) could weigh on Dapagliflozin through efficacy or safety read-through uncertainty if follow-through weakens.
Clinical risk from ClinicalTrials.gov (The HEARTFELT Study) could weigh on Dapagliflozin through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

If dapagliflozin demonstrates efficacy in this new indication, it could capture additional market share in the heart failure segment, potentially increasing revenue streams for the product.
Upside for Dapagliflozin may improve if Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026 (FDA) delivers favorable follow-through.
Positive results may enhance dapagliflozin's positioning in heart failure treatment, influencing competitive strategies for similar agents.

What Would Change This Assessment

This becomes more urgent if Monitor the trial outcomes, particularly the TAPSE/PASP ratio changes at 7 months.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026
FDAhigh relevance
Sub-indication match (cardiology)
FDA document
View source
FDA AP — BAXFENDY (ORIG)
FDAmedium relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
FDA AP — BAXFENDY (ORIG)
FDAmedium relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
FDA AP — BAXFENDY (ORIG)
FDAmedium relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
FDA AP — DAPAGLIFLOZIN (SUPPL)
FDAmedium relevance
Entity match (dapagliflozin)
FDA document
View source
FDA TA — DAPAGLIFLOZIN (ORIG)
FDAmedium relevance
Entity match (dapagliflozin)
FDA document
View source
FDA TA — DAPAGLIFLOZIN (ORIG)
FDAmedium relevance
Entity match (dapagliflozin)
FDA document
View source
FDA AP — DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Entity match (dapagliflozin)
FDA document
View source

Effectiveness of Video Monitoring and Care Transition for Heart Failure Patients (EVIT-HF): Randomized Clinical Trial
ClinicalTrials.govhigh relevance
Sub-indication match (cardiology); Entity match (heart failure patients)
FDA document
View source
ImpleMEntation of Digital-first Care deLiverY Model for Heart Failure in Uganda
ClinicalTrials.govhigh relevance
Sub-indication match (cardiology)
FDA document
View source
Association Between Circulating BDNF Levels and Atrial Cardiomyopathy in Patients Undergoing Ablation for Persistent Atrial Fibrillation
ClinicalTrials.govhigh relevance
Sub-indication match (cardiology)
FDA document
View source
The HEARTFELT Study
ClinicalTrials.govhigh relevance
Sub-indication match (cardiology)
FDA document
View source
Mechanisms of Myocardial Injury and Ischemia in Patients With Rapid Atrial Fibrillation
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Left Atrial and Left Ventricular Structural and Functional Evaluation by CCTA for Predicting Post-Ablation Outcomes in Patients With Atrial Fibrillation
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Posterosuperior Bundle Pacing for Prevention of Atrial Fibrillation in Patients With Sinus Node Dysfunction
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Digital Management Improves Outcomes in Early Cardiogenic Shock Patients
Humanexa Signalshigh relevance
Sub-indication match (cardiology)
Ravulizumab Shows Promise in Reducing Delayed Graft Function in Kidney Transplant Patients
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities

Safety and efficacy of ashwagen (a standardized withania somnifera extract) in stress and anxiety with hypertension and associated cardiometabolic risk factors: a randomized, placebo-controlled trial.
PubMedhigh relevance
Sub-indication match (cardiology)
FDA document
View source
Wrist-Ankle Acupuncture on Postoperative Nausea and Vomiting Prophylaxis in High-Risk Female Patients: A Pragmatic, Randomized, Single-Blind, Sham-Controlled Trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effects of fecal microbiota transplantation and probiotics on the gut microbiome in antibiotic-treated septic patients: A pilot randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Oro-esophageal feeding for tracheostomized patients with severe traumatic brain injury: a randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Safety, tolerability, and pharmacokinetics/-dynamics of the dipeptidyl peptidase 3-inhibiting antibody Procizumab in a first-in-human trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
RBM15B-mediated m6A modification of FOXM1 activates the AURKA/TPX2 axis to promote epithelial-mesenchymal transition-driven endometrial cancer progression.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Immune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Dapagliflozin
Heart Failure Patients

Commercial impact

medium

If dapagliflozin demonstrates efficacy in this new indication, it could capture additional market share in the heart failure segment, potentially increasing revenue streams for the product.

Regulatory impact

medium

Successful trial results could pave the way for regulatory submissions to expand dapagliflozin's label, impacting compliance and approval timelines for new indications.

What to watch

Monitor the trial outcomes, particularly the TAPSE/PASP ratio changes at 7 months.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.